

Financial Statements



**For the Year Ended December 31, 2025
With Summarized Financial
Information for 2024**

Colorectal Cancer Alliance, Inc.

Table of Contents
For the Year Ended December 31, 2025
With Summarized Financial Information for 2024

Independent Auditor's Report	2
Statement of Financial Position	5
Statement of Activities and Change in Net Assets	6
Statement of Functional Expenses	7
Statement of Cash Flows	8
Notes to Financial Statements	10



INDEPENDENT AUDITOR'S REPORT

Board of Directors
Colorectal Cancer Alliance, Inc.
Washington, D.C.

Opinion

We have audited the accompanying financial statements of Colorectal Cancer Alliance, Inc. (the Alliance), which comprise the statement of financial position as of December 31, 2025, and the related statements of activities and change in net assets, functional expenses and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Alliance as of December 31, 2025, and the change in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Alliance and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

4550 MONTGOMERY AVENUE • SUITE 800 NORTH • BETHESDA, MARYLAND 20814
(301) 951-9090 • WWW.GRFCPA.COM

MEMBER OF CPAMERICA INTERNATIONAL, AN AFFILIATE OF CROWE GLOBAL
MEMBER OF THE AMERICAN INSTITUTE OF CERTIFIED PUBLIC ACCOUNTANTS' PRIVATE COMPANIES PRACTICE SECTION

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Alliance's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Alliance's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Alliance's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Report on Summarized Comparative Information

We have previously audited the Alliance's 2024 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated July 15, 2025. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2024, is consistent, in all material respects, with the audited financial statements from which it has been derived.

A handwritten signature in cursive script that reads "Gelman Rosenberg & Freedman".

August 17, 2026

Colorectal Cancer Alliance, Inc.

Statement of Financial Position
As of December 31, 2025
With Summarized Financial Information for 2024

ASSETS

	2025	2024
Cash and cash equivalents	\$ 1,953,347	\$ 4,165,366
Investments	5,714,368	5,192,264
Grants and contributions receivable, net	4,201,581	6,077,341
Prepaid expenses and other assets	79,670	169,904
Property and equipment, net	-	272,751
Intangible assets	40,000	-
Security deposit	69,653	73,822
Operating lease right-of-use asset, net	-	399,398
Total Assets	\$ 12,058,619	\$ 16,350,846

LIABILITIES AND NET ASSETS

LIABILITIES

Accounts payable and accrued liabilities	\$ 3,133,775	\$ 998,462
Accrued salaries and related benefits	588,540	772,350
Operating lease liability	-	388,678
Total liabilities	3,722,315	2,159,490

NET ASSETS

Without donor restrictions	1,624,203	3,464,442
With donor restrictions	6,712,101	10,726,914
Total net assets	8,336,304	14,191,356
Total Liabilities and Net Assets	\$ 12,058,619	\$ 16,350,846

See accompanying notes to financial statements.

Colorectal Cancer Alliance, Inc.

**Statement of Activities and Change in Net Assets
For the Year Ended December 31, 2025
With Summarized Financial Information for 2024**

	2025			2024
	Without Donor Restrictions	With Donor Restrictions	Total	Total
SUPPORT AND REVENUE				
Contributed nonfinancial assets	\$ 40,932,023	\$ 5,293,758	\$ 46,225,781	\$ 45,771,298
Grants and contributions	17,750,709	-	17,750,709	21,350,783
Net investment return	619,449	-	619,449	471,313
Merchandise sales	91,881	-	91,881	175,797
Other income	38,723	-	38,723	47,966
Loss on uncollectable grants and contributions	(25,004)	(220,000)	(245,004)	(237,620)
Loss on disposal of leasehold improvements	(213,458)	-	(213,458)	-
Net assets released from donor restrictions	9,088,571	(9,088,571)	-	-
Total support and revenue	68,282,894	(4,014,813)	64,268,081	67,579,537
EXPENSES				
Program Services:				
Screening Awareness and Navigation	29,340,926	-	29,340,926	3,966,902
Cancer Care	23,722,819	-	23,722,819	47,800,468
Project Cure CRC	8,849,029	-	8,849,029	4,712,320
Grassroots Community Engagement and Advocacy	3,733,098	-	3,733,098	2,524,860
Total program services	65,645,872	-	65,645,872	59,004,550
Supporting Services:				
Fundraising	2,858,181	-	2,858,181	4,106,802
Management and General	1,760,611	-	1,760,611	1,443,915
Total supporting services	4,618,792	-	4,618,792	5,550,717
Total expenses	70,264,664	-	70,264,664	64,555,267
Change in net assets before other item	(1,981,770)	(4,014,813)	(5,996,583)	3,024,270
OTHER ITEM				
Transfer of net assets	141,531	-	141,531	-
Change in net assets	(1,840,239)	(4,014,813)	(5,855,052)	3,024,270
Net assets at beginning of year	3,464,442	10,726,914	14,191,356	11,167,086
Net Assets at End of Year	\$ 1,624,203	\$ 6,712,101	\$ 8,336,304	\$ 14,191,356

See accompanying notes to financial statements.

Colorectal Cancer Alliance, Inc.

**Statement of Functional Expenses
For the Year Ended December 31, 2025
With Summarized Financial Information for 2024**

	2025								2024	
	Program Services					Supporting Services				
	Screening Awareness and Navigation	Cancer Care	Project Cure CRC	Grassroots Community Engagement and Advocacy	Total Program Services	Fundraising	Management and General	Total Supporting Services	Total Expenses	Total Expenses
Donated services	\$ 25,155,496	\$ 21,000,285	\$ -	\$ -	\$ 46,155,781	\$ 70,000	\$ -	\$ 70,000	\$ 46,225,781	\$ 45,692,076
Projects	1,271,237	1,000,144	4,380,873	719,302	7,371,556	792,522	6,683	799,205	8,170,761	6,292,779
Personnel	1,540,312	1,254,296	1,360,859	1,547,023	5,702,490	1,268,535	1,156,661	2,425,196	8,127,686	7,058,327
Facilities	256,045	194,110	2,244,832	298,348	2,993,335	266,162	132,691	398,853	3,392,188	755,105
Professional fees	819,829	65,002	727,382	749,182	2,361,395	161,669	383,863	545,532	2,906,927	3,373,429
Travel	133,851	174,453	106,606	166,077	580,987	181,748	63,044	244,792	825,779	668,588
Operations	164,156	34,529	28,477	253,166	480,328	117,545	17,669	135,214	615,542	714,963
Total	\$ 29,340,926	\$ 23,722,819	\$ 8,849,029	\$ 3,733,098	\$ 65,645,872	\$ 2,858,181	\$ 1,760,611	\$ 4,618,792	\$ 70,264,664	\$ 64,555,267

See accompanying notes to financial statements.

Colorectal Cancer Alliance, Inc.

**Statement of Cash Flows
For the Year Ended December 31, 2025
With Summarized Financial Information for 2024**

	<u>2025</u>	<u>2024</u>
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	\$ (5,855,052)	\$ 3,024,270
Adjustments to reconcile change in net assets to net cash (used) provided by operating activities:		
Net realized and unrealized gain on investments	(419,058)	(262,076)
Loss on uncollectable grants and contributions	245,004	237,620
Change in discount on grants and contributions receivable	166,365	(24,629)
Depreciation and amortization of property and equipment	59,293	71,153
Intangible assets included in transfer of net assets	(40,000)	-
Amortization of operating lease right-of-use asset	399,398	387,243
Loss on disposal of leasehold improvements	213,458	-
Gain on lease termination	-	(402,582)
Decrease (increase) in:		
Grants and contributions receivable	1,709,395	(829,349)
Prepaid expenses and other assets	113,452	(41,029)
Security deposit	4,169	-
Increase (decrease) in:		
Accounts payable and accrued liabilities	2,135,313	169,898
Accrued salaries and related benefits	(183,810)	(34,819)
Operating lease liability	(388,678)	(435,217)
Net cash (used) provided by operating activities	<u>(1,840,751)</u>	<u>1,860,483</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of investments	(6,432,867)	(2,236,430)
Proceeds from sales of investments	6,061,599	2,106,902
Net cash used by investing activities	<u>(371,268)</u>	<u>(129,528)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Payments on line of credit	-	(1,617,429)
Net cash used by financing activities	<u>-</u>	<u>(1,617,429)</u>
Net (decrease) increase in cash and cash equivalents	(2,212,019)	113,526
Cash and cash equivalents at beginning of year	4,165,366	4,051,840
Cash and Cash Equivalents at End of Year	<u>\$ 1,953,347</u>	<u>\$ 4,165,366</u>

See accompanying notes to financial statements.

Colorectal Cancer Alliance, Inc.

Statement of Cash Flows
For the Year Ended December 31, 2025
With Summarized Financial Information for 2024

	2025	2024
SUPPLEMENTAL INFORMATION		
Interest Paid	\$ -	\$ 7,691
SCHEDULE OF NONCASH TRANSACTIONS		
Donated Securities	\$ 252,550	\$ 249,870

See accompanying notes to financial statements.

Colorectal Cancer Alliance, Inc.

Notes to Financial Statements December 31, 2025

1. Summary of Significant Accounting Policies

Organization

Colorectal Cancer Alliance, Inc. (the Alliance) was formed in 1999 as a non-profit organization in accordance with the laws of the State of Delaware. The mission of the Alliance is to end colon and rectal cancer and support the nearly 50,000 afflicted with the disease each year. This is achieved by supporting preventative measures, accelerating research toward cures, and providing cancer care support services to patients, families and caregivers.

Program Services

Screening Awareness and Navigation - The Alliance promotes prevention, screening, and early detection through a variety of awareness initiatives, partnerships, screening projects and tools, and campaigns at the national and local level.

Cancer Care - The Alliance patient and family support program provides cancer care education, medical advocacy, and direct navigation through a helpline, chat and group chat navigation, online community forums, a buddy program, and a national conference.

Project Cure CRC - The Alliance accelerates research aimed at discovering innovative treatments and ultimately a cure for the disease through project Cure CRC, a groundbreaking initiative convening the world's top scientists at an annual summit and connecting cutting-edge studies, clinical trials, and collaborations to drive progress toward a cure.

Grassroots Community Engagement and Advocacy - The Alliance fosters community engagement through outreach and advocacy efforts across the nation, and in local communities that give the opportunity to share their stories, connect with each other, and become leaders to amplify the Alliance's mission to end this disease.

Basis of Presentation

The accompanying financial statements are presented on the accrual basis of accounting, and in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) related to non-profit entities. As such, net assets are reported within two net asset classifications: without donor restrictions and with donor restrictions. Descriptions of the two net asset categories are as follows:

- **Net Assets without Donor Restrictions** - Net assets available for use in general operations and not subject to donor restrictions are recorded as "net assets without donor restrictions". Net assets set aside solely through the actions of the Board are referred to as Board designated and are also reported as net assets without donor restrictions. However, there are no Board designated net assets.

Colorectal Cancer Alliance, Inc.

Notes to Financial Statements December 31, 2025

1. Summary of Significant Accounting Policies (Continued)

Basis of Presentation (Continued)

- **Net Assets with Donor Restrictions** - Net assets may be subject to donor-imposed stipulations that are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Donor-imposed restrictions are released when the restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. However, there are no endowment fund net assets.

The financial statements include certain prior year summarized comparative information in total but not by net asset class; such information does not include sufficient detail to constitute a presentation in conformity with generally accepted accounting principles. Accordingly, such information should be read in conjunction with the Alliance's financial statements for the year ended December 31, 2024, from which the summarized information was derived.

Cash and Cash Equivalents

The Alliance considers all highly liquid investments with maturities of three months or less, which are not part of the investment portfolio, to be cash and cash equivalents. Bank deposit accounts are insured by the Federal Deposit Insurance Corporation ("FDIC") up to a limit of \$250,000. At times during the year, the Alliance maintains cash balances in excess of the FDIC insurance limits. Management believes the risk in these situations to be minimal.

Investments

Investments are recorded at their readily determinable fair value. Interest, dividends, and realized and unrealized gains and losses are presented in net investment return, which includes investment expenses paid to external investment advisors, in the accompanying Statement of Activities and Change in Net Assets.

Investments acquired by gift, such as donated securities, are recorded at their fair value at the date of the gift. The Alliance's policy is to liquidate all gifts of investments as soon as possible after the gift.

Grants and Contributions Receivable

Grants and contributions receivable include unconditional promises to give that are expected to be collected in future years. Grants and contributions receivable are recorded at their fair value, which is measured as the net present value of the future cash flows. The discount on long-term grants and contributions is computed using the risk-adjusted interest rates applicable to the years in which the promises to give were received. Amortization of the discount is included in contributions.

Colorectal Cancer Alliance, Inc.

**Notes to Financial Statements
December 31, 2025**

1. Summary of Significant Accounting Policies (Continued)

Grants and Contributions Receivable (Continued)

Management reviews grants and contributions receivable on a periodic basis for collectability. Each receivable balance is assessed based on management's knowledge of and relationship with the donor and the age of the receivable balance. As a result of these reviews, receivable balances for which collection is deemed doubtful are charged to loss on uncollectable grants and contributions and an allowance is recorded. While certain balances were written off during the year, management believes all balances to be collectable as of December 31, 2025. Therefore, there was no allowance for uncollectable grants and contributions receivable as of December 31, 2025.

Property and Equipment

Property and equipment in excess of \$5,000 are capitalized and stated at cost. Property and equipment are depreciated or amortized on a straight-line basis over the estimated useful lives of the related assets, generally three to five years. The cost of maintenance and repairs is recorded as expenses are incurred. Depreciation and amortization expense totaled \$59,293 for the year ended December 31, 2025.

Intangible Assets

Intangible assets consist of donor mailing lists which have a finite useful life of four years. Intangible assets are amortized on a straight-line basis over their useful life. The amortization period and amortization method for an intangible asset with a finite useful life reflects the pattern in which the asset's future economic benefits are expected to be consumed. The carrying value of the intangible asset totaled \$40,000 as of December 31, 2025. There was no accumulated amortization as of December 31, 2025.

Leases

The Alliance determines if an arrangement is or contains a lease at inception, which is the date on which the terms of the contract are agreed to and the agreement creates enforceable rights and obligations. The Alliance also considers whether its services agreements include the right to control the use of an asset.

The Alliance recognizes most leases on its Statement of Financial Position as a right-of-use (ROU) asset representing the right to use an underlying asset and a lease liability representing the obligation to make lease payments over the lease term, measured on a discounted basis. Leases are classified as either finance leases or operating leases based on certain criteria as defined by GAAP. The Alliance made an accounting policy election not to recognize ROU assets and lease liabilities for leases with a term of 12 months or less. However, there were no short-term leases. For all other leases, ROU assets and lease liabilities are measured based on the present value of lease payments over the term of the lease at the commencement or modification date.

Colorectal Cancer Alliance, Inc.

Notes to Financial Statements

December 31, 2025

1. Summary of Significant Accounting Policies (Continued)

Leases (Continued)

The Alliance made the accounting policy election to use a risk-free discount rate, which is aligned with the lease term. The Alliance has made an accounting policy election that allows lessees to choose not to separate lease and non-lease components by class of underlying asset and is applying this expedient to all relevant asset classes.

Income Taxes

The Alliance is exempt from Federal income tax under Section 501(a) of the Internal Revenue Code ("IRC"), as an organization described in IRC Section 501(c)(3). The Alliance has no unrelated business income activities. Accordingly, no provision for income taxes has been made in the accompanying financial statements. The Alliance is not a private foundation.

Contributed Nonfinancial Assets

Contributed nonfinancial assets are recorded at their estimated fair value as of the date of the gift and consisted of donated media services. Donated media services are valued based on the prevailing fair market value of the services received. Contributed services are recognized as contributions if the services (a) create or enhance nonfinancial assets or (b) require specialized skills, are performed by people with those skills, and would otherwise be purchased by the Alliance. As reported in the accompanying Statement of Activities and Change in Net Assets, a portion of the contributed nonfinancial assets were restricted by donors. In addition, none of contributed nonfinancial assets were monetized through sales to customers.

Support from Grants and Contributions

Grants and contributions are recognized in the appropriate category of net assets in the period received. The Alliance performs an analysis of the individual grant or contribution agreement to determine if the funding stream follows the contribution rules or if it should be recorded as an exchange transaction, depending upon whether the transaction is deemed reciprocal or nonreciprocal in accordance with ASC Topic 958.

Support from grants and contributions is recognized upon notification of the award and satisfaction of all conditions, if applicable. Conditional promises to give are not recognized until the conditions on which they depend are substantially met. Grants and contributions that are unconditional but have donor restrictions are recognized as "without donor restrictions" only to the extent of actual expenses incurred in compliance with the donor-imposed restrictions and satisfaction of time restrictions. Grants and contributions with donor restrictions either in excess of expenses incurred or with time restrictions are shown as net assets with donor restrictions in the accompanying financial statements.

Conditional grants and contributions contain a right of return and a measurable barrier. Conditional grants and contributions received in advance of meeting specified conditions established by donors are recorded as refundable advances. However, the Alliance had no refundable advances as of December 31, 2025.

Colorectal Cancer Alliance, Inc.

**Notes to Financial Statements
December 31, 2025**

1. Summary of Significant Accounting Policies (Continued)

Support from Grants and Contributions (Continued)

In addition, the Alliance may obtain funding source agreements related to conditional grants and contributions, which will be received in future years. However, the Alliance had no conditional contributions to be received in future years as of December 31, 2025.

Revenue from Contracts with Customers

The Alliance's revenue from merchandise sales is the most significant revenue stream that is treated as exchange transaction revenue following ASC Topic 606. Revenue from contracts with customers is recorded when the performance obligations are met. The Alliance has elected to opt out of all disclosures not required for nonpublic entities. Transaction price is based on sales price. Amounts received in advance of satisfying performance obligations are recorded as deferred revenue. The Alliance's contracts with customers generally have initial terms of one year or less. Merchandise sales are recognized as revenue at the point in time when the merchandise is shipped to the customer. Cost of goods sold is presented in the Grassroots Community Engagement and Advocacy functional area in the Statement of Functional Expenses and totaled \$116,597 for the year ended December 31, 2025.

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.

Advertising

The Alliance expenses advertising costs as incurred. Excluding the contributed media services, which are described in Note 9, advertising expense totaled \$602,391 for the year ended December 31, 2025.

Functional Allocation of Expenses

The costs of providing the Alliance's programs and supporting services have been summarized on a functional basis in the Statement of Activities and Change in Net Assets. Accordingly, certain costs have been allocated among the programs and supporting services benefited. Expenses directly attributed to a specific functional area are reported as direct expenses within that functional area and indirect expenses that benefited more than one functional area, such as personnel costs, were allocated based on estimated time and effort.

Risks and Uncertainties

The Alliance invests in investment securities, which are exposed to various risks such as interest rates, market and credit risks.

Colorectal Cancer Alliance, Inc.

Notes to Financial Statements
December 31, 2025

1. Summary of Significant Accounting Policies (Continued)

Risks and Uncertainties (Continued)

Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the accompanying financial statements.

2. Investments and Fair Value Measurements

In accordance with FASB ASC 820, *Fair Value Measurement*, the Alliance has categorized its financial instruments, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure the financial instruments fall within different levels of hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

Investments recorded in the accompanying Statement of Financial Position are categorized based on the inputs to valuation techniques as follows:

Level 1. These are investments where values are based on unadjusted quoted prices for identical assets in an active market the Alliance has the ability to access.

Level 2. These are investments where values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuation techniques that utilize inputs that are observable either directly or indirectly for substantially the full-term of the investments.

Level 3. These are investments where inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Following is a description of the valuation methodology used for investments measured at fair value. There have been no changes in the methodologies used and there were no transfers between levels in the fair value hierarchy during the year ended December 31, 2025. Transfers between levels are recorded at the end of the reporting period, if applicable.

- *Common Stocks and Options* - Valued at the closing price reported on the active market in which the individual securities are traded.
- *Exchange-Traded Funds* - Valued at the closing price reported on the active market in which the funds are traded.
- *Mutual Funds* - Valued at the daily closing price as reported by the fund. Mutual funds held by the Alliance are open-end mutual funds that are registered with the SEC. These funds are required to publish their daily value and to transact at that price. Mutual funds held by the Alliance are deemed to be actively traded.

Colorectal Cancer Alliance, Inc.

**Notes to Financial Statements
December 31, 2025**

2. Investments and Fair Value Measurements (Continued)

- *Money Market Funds* - The money market funds are open-end funds that are registered with the Securities and Exchange Commission (SEC) and are deemed to be actively traded.
- *Series C Stock* - Valued based on the Alliance's percent ownership in a private cancer research company.
- *Non-Fungible Tokens (NFTs)* - Valued based on the average exchange sales price of similar NFTs. An NFT is a unique digital asset that is stored on a blockchain, representing ownership of a specific digital item. Each NFT is unique and cannot be directly exchanged for another NFT.

The table below summarizes investments, which are measured at fair value on a recurring basis, by level within the fair value hierarchy as of December 31, 2025:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Common stocks and options	\$ 2,472,940	\$ -	\$ -	\$ 2,472,940
Exchange-traded funds	3,008,530	-	-	3,008,530
Mutual funds	114,940	-	-	114,940
Money market funds	90,640	-	-	90,640
Series C stock	-	-	25,000	25,000
Non-fungible tokens	-	-	2,318	2,318
Total Investments	<u>\$ 5,687,050</u>	<u>\$ -</u>	<u>\$ 27,318</u>	<u>\$ 5,714,368</u>

The Alliance's Level 3 investments did not have any activity for the year ended December 31, 2025. There were no new contributions and there was no change in fair value.

Net investment return consisted of the following for the year ended December 31, 2025:

Interest and dividends	\$ 254,500
Net realized and unrealized gains on investments	419,058
Investment expenses	(54,109)
Net Investment Return	<u>\$ 619,449</u>

3. Grants and Contributions Receivable

Grants and contributions receivable that are due in more than one year have been recorded at the net present value of their estimated future cash flows using risk-adjusted discount rates ranging from 1.30% to 3.84%, based on the date the Alliance received the gift.

Colorectal Cancer Alliance, Inc.

**Notes to Financial Statements
December 31, 2025**

3. Grants and Contributions Receivable (Continued)

Grants and contributions receivable are expected to be collected as follows as of December 31, 2025:

Less than one year	\$ 3,056,308
One to five years	1,356,803
Subtotal	<u>4,413,111</u>
Less: Discount to net present value	(211,530)
Grants and Contributions Receivable, Net	<u><u>\$ 4,201,581</u></u>

4. Line of Credit

The Alliance has a liquidity line of credit secured by investments held by its investment manager. The line of credit continues in effect until terminated by either party. The maximum amount of credit that may be extended to the Alliance is based on the eligible securities maintained in the investment portfolio. The terms of the line of credit agreement require that the Alliance complies with certain covenants. There were no drawdowns during the year ended December 31, 2025, and no outstanding balance on the line of credit as of December 31, 2025.

5. Joint Costs

The Alliance incurred joint costs totaling \$3,370,554 related to events that were held during the year ended December 31, 2025. The joint costs were allocated to the following program and supporting services for the year ended December 31, 2025:

Program Services:

Screening Awareness and Navigation	\$ 999,647
Grassroots Community Engagement and Advocacy	1,896,719

Supporting Services:

Fundraising	474,188
-------------	---------

Total	<u><u>\$ 3,370,554</u></u>
--------------	----------------------------

6. Net Assets with Donor Restrictions

Net assets with donor restrictions consist of the following as of December 31, 2025:

Purpose Restricted:

Project Cure CRC	\$ 4,819,320
Screening Awareness and Navigation	458,235
Cancer Care	178,753
Grassroots Community Engagement and Advocacy	145,520

Subtotal	<u>5,601,828</u>
-----------------	------------------

Time-Restricted	1,110,273
-----------------	-----------

Total Net Assets with Donor Restrictions	<u><u>\$ 6,712,101</u></u>
---	----------------------------

Colorectal Cancer Alliance, Inc.

Notes to Financial Statements
December 31, 2025

6. Net Assets with Donor Restrictions (Continued)

Net assets released from donor restrictions consisted of the following for the year ended December 31, 2025:

Purpose Restrictions Accomplished:

Project Cure CRC	\$ 6,938,877
Screening Awareness and Navigation	812,899
Cancer Care	213,760
Grassroots Community Engagement and Advocacy	149,839
Subtotal	8,115,375
Expiration of time restrictions	973,196
Total Net Assets Released from Donor Restrictions	\$ 9,088,571

7. Liquidity and Availability

The Alliance has a policy to structure its financial assets to be available and liquid as its obligations become due. Grants and contributions receivable are subject to implied time restrictions, but a portion are expected to be collected within one year. The Alliance monitors its liquidity so that it is able to meet its operating needs and other contractual commitments while maximizing the investment of its excess operating cash. The Alliance has a goal to maintain financial assets on hand to meet 90 days of normal operating expenses.

Financial assets available for use for general expenditures within one year of the Statement of Financial Position date comprise the following as of December 31, 2025:

Cash and cash equivalents	\$ 1,953,347
Investments	5,714,368
Grants and contributions receivable, net	4,201,581
Subtotal financial assets available within one year	11,869,296
Less: Net assets with donor restrictions for purpose	(5,601,828)
Less: Net assets with donor restrictions for time (long-term only)	(1,110,273)
Financial Assets Available for Use Within One Year	\$ 5,157,195

8. Contributed Nonfinancial Assets

The Alliance was the beneficiary of contributed nonfinancial assets which allowed it to provide greater resources towards various programs. The contributed nonfinancial assets have been recorded in both support and functional expenses on the Statement of Activities and Change in Net Assets.

The contributed nonfinancial assets included in support totaled \$46,225,781 and primarily consisted of donated advertising services for the year ended December 31, 2025.

Colorectal Cancer Alliance, Inc.

Notes to Financial Statements December 31, 2025

8. Contributed Nonfinancial Assets (Continued)

The contributed nonfinancial assets have also been recorded in the following functional expense categories for the year ended December 31, 2025:

Screening Awareness and Navigation	\$ 25,155,496
Cancer Care	21,000,285
Fundraising	70,000
Total	\$ 46,225,781

9. Transfer of Net Assets

During 2024, the Board of Directors approved a motion to accept the net assets of Colon Cancer Foundation (CCF), an unrelated 501(c)(3) organization organized in accordance with the laws of the State of New York. CCF was dedicated to a world without colorectal cancer and focused on promoting on-time screenings, funding research for early-onset cases, and providing support. CCF is actively transitioning many of its initiatives, such as resources for patients and research grants, to the Alliance. Therefore, CCF transferred net assets totaling \$141,531 to the Alliance during the year ended December 31, 2025. The transferred net assets were without donor restrictions and included cash totaling \$101,531 plus an intangible asset totaling \$40,000. CCF will be legally dissolved after its program activities are successfully transferred to the Alliance.

10. Lease Commitments

Old Lease

The Alliance had an operating lease for office space in Washington, D.C, the amended version of which was originally scheduled to terminate in October 2029. However, during October 2024, the Alliance exercised its option to terminate the lease effective on October 31, 2025. As a result, the Alliance rented swing office space in Washington, D.C. on a month-to-month basis during November and December 2025. The rent for the swing office space was \$3,050 per month.

Lease cost is included in facilities expense in the accompanying Statement of Functional Expenses and totaled \$413,178 for the year ended December 31, 2025. Cash paid for base rent totaled \$390,259 for the year ended December 31, 2025.

New Lease

During June 2025, the Alliance signed an operating lease for a new office space in Washington, D.C. The lease commencement date was February 11, 2026. The new operating lease will expire on October 31, 2037, and includes both extension and early termination options, which are subject to certain conditions. As stipulated in the lease agreement, the first 20 months of rent will be fully abated and base monthly rent will begin at \$23,218 on the 21st month of the lease. Base monthly rent will increase by 2.5% each subsequent lease year. Total future rental payments for the entire term under the new operating lease will be \$3,245,275.

Colorectal Cancer Alliance, Inc.

Notes to Financial Statements December 31, 2025

11. Retirement Plan

The Alliance provides retirement benefits to eligible employees through a 401(k) defined contribution plan (the Plan). In accordance with the provisions of the Plan, the Alliance contributes an amount for each employee based on the level of the employee's contribution to the Plan. The Alliance's contributions to the Plan have been included in Personnel in the accompanying Statement of Functional Expenses and totaled \$214,361 for the year ended December 31, 2025.

12. Concentration of Revenue

Grants and contributions receivable include amounts due from one donor which comprises 30% of the Alliance's total grants and contributions receivable (approximately \$1.2 million) as of December 31, 2025. The Alliance has no reason to believe that its relationship with the donor will be discontinued in the foreseeable future and the Alliance considers the receivable to be fully collectable.

13. Subsequent Events

In preparing these financial statements, the Alliance has evaluated events and transactions for potential recognition or disclosure through August 17, 2026, the date the financial statements were issued.

During February 2026, the Alliance's new operating lease for office space commenced (see Note 10).

During March 2026, the Alliance drew down proceeds totaling \$1,100,000 on its line of credit to fund ongoing operations.

During May 2026, the Alliance established Project Cure CRC, LLC (CRC LLC) as a single member limited liability company in accordance with the laws of the State of Delaware. The Alliance is the sole member of CRC LLC, which will manage the data related to the Project Cure CRC program. The Alliance and CRC LLC will be consolidated for financial reporting purposes beginning in 2026.

During May 2026, the Alliance received an unconditional promise to give of approximately \$7 million, which is restricted by the donor to support the Project Cure CRC program.